Business Description
Disc Medicine Inc
NAICS : 325412
SIC : 2834
ISIN : US2546041011
Share Class Description:
IRON: Ordinary SharesTotal Employee Number:
165Compare
Compare
Traded in other countries / regions
IRON.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2021-02-08Description
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.79 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.25 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 49.5 | |||||
3-Year EPS without NRI Growth Rate | 48.9 | |||||
3-Year FCF Growth Rate | 49.9 | |||||
3-Year Book Growth Rate | 24.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.93 | |||||
9-Day RSI | 49.75 | |||||
14-Day RSI | 53.29 | |||||
3-1 Month Momentum % | 5.44 | |||||
6-1 Month Momentum % | 12.05 | |||||
12-1 Month Momentum % | 25.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 24.14 | |||||
Quick Ratio | 24.14 | |||||
Cash Ratio | 23.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.6 | |||||
Shareholder Yield % | -7.53 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -37.71 | |||||
ROA % | -34.27 | |||||
ROIC % | -2489 | |||||
3-Year ROIIC % | -1780.42 | |||||
ROC (Joel Greenblatt) % | -10821.16 | |||||
ROCE % | -35.16 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.76 | |||||
Price-to-Tangible-Book | 4.76 | |||||
EV-to-EBIT | -9.98 | |||||
EV-to-EBITDA | -9.99 | |||||
EV-to-Forward-Revenue | 77.09 | |||||
EV-to-FCF | -12.22 | |||||
| Price-to-Net-Current-Asset-Value | 4.78 | |||||
| Price-to-Net-Cash | 4.89 | |||||
Earnings Yield (Greenblatt) % | -10.02 | |||||
FCF Yield % | -6.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IRON
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Disc Medicine Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.58 | ||
| Beta | 2.089 | ||
| 3-Year Sharpe Ratio | 0.5 | ||
| 3-Year Sortino Ratio | 0.77 | ||
| Volatility % | 41.19 | ||
| 14-Day RSI | 53.29 | ||
| 14-Day ATR ($) | 2.899558 | ||
| 20-Day SMA ($) | 79.7355 | ||
| 12-1 Month Momentum % | 25.13 | ||
| 52-Week Range ($) | 40.0001 - 99.5 | ||
| Shares Outstanding (Mil) | 38.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Disc Medicine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Disc Medicine Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 181 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 69 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 73.67 (-1.06%) | ||
| General meeting for 2026 | 2026-06-18 09:00 | 70.21 (+0.13%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:10 | 68.00 (-4.36%) | ||
| H.C. Wainwright 3rd Annual BioConnect Investor Conference | 2026-05-19 16:30 | 66.85 (-4.12%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 67.64 (+1.23%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 15:40 | 61.18 (+3.40%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 09:50 | 66.54 (+2.61%) |
Show
Entries
Disc Medicine Inc Frequently Asked Questions
What is Disc Medicine Inc(IRON)'s stock price today?
The current price of IRON is $80.01. The 52 week high of IRON is $99.50 and 52 week low is $40.00.
When is next earnings date of Disc Medicine Inc(IRON)?
The next earnings date of Disc Medicine Inc(IRON) is 2026-11-06 Est..
Does Disc Medicine Inc(IRON) pay dividends? If so, how much?
Disc Medicine Inc(IRON) does not pay dividend.
Press Release
Articles on Disc Medicine Inc
Opaleye Management Inc. Expands Stake in Grace Therapeutics Inc (GRCE) Despite Market Headwinds
4 days ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers